Back to Search
Start Over
Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
- Source :
-
Clinical breast cancer [Clin Breast Cancer] 2018 Apr; Vol. 18 (2), pp. e237-e244. Date of Electronic Publication: 2017 Nov 09. - Publication Year :
- 2018
-
Abstract
- Background: Immune reaction with tumor-infiltrating lymphocytes (TILs) has been extensively investigated in breast cancer. Programmed cell death 1 and its ligand (PD-L1) are key physiologic suppressors of cytotoxic immune reaction. However, the combination of TILs with PD-L1 expression has not been well studied in breast cancer.<br />Patients and Methods: A multi-color immunohistochemical multiplex assay simultaneously detecting PD-L1, CD8, and CD163 was performed on biopsy whole sections from 123 HER2-positive (HER2 <superscript>+</superscript> ) breast cancers, including 64 treated with anti-HER2 neoadjuvant therapy and subsequent resection.<br />Results: PD-L1 expression was identified in 88 cases (72%) including 21 (17%) in tumor cells and 67 (55%) in immune cells. PD-L1 expression was positively associated with high Nottingham grade, high nuclear grade, and a high level of CD8 <superscript>+</superscript> and CD163 <superscript>+</superscript> cells. Among the 64 patients who received neoadjuvant therapy, 39 had pathologic complete remission (pCR) and 25 had incomplete response. Multivariate analysis showed progesterone receptor negativity, HER2/chromosome 17 centromere (CEN17) ratio and intratumoral CD8 <superscript>+</superscript> cells were significantly associated with pCR. Furthermore, all patients with intratumoral CD8 <superscript>+</superscript> cells but no PD-L1 expression achieved pCR.<br />Conclusion: Our data have shown that examination of intratumoral CD8 <superscript>+</superscript> cells together with PD-L1 expression proves useful in predicting response to anti-HER2 targeted therapy in patients with HER2 <superscript>+</superscript> breast cancer.<br /> (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological pharmacology
Antineoplastic Combined Chemotherapy Protocols pharmacology
B7-H1 Antigen metabolism
Breast pathology
Breast surgery
Breast Neoplasms immunology
Breast Neoplasms pathology
Female
Humans
Lymph Nodes pathology
Lymphocytes, Tumor-Infiltrating immunology
Lymphocytes, Tumor-Infiltrating metabolism
Mastectomy
Middle Aged
Neoadjuvant Therapy methods
Prognosis
Receptor, ErbB-2 antagonists & inhibitors
Receptor, ErbB-2 immunology
Receptor, ErbB-2 metabolism
Treatment Outcome
Antineoplastic Agents, Immunological therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
B7-H1 Antigen analysis
Breast Neoplasms drug therapy
Immunohistochemistry methods
Subjects
Details
- Language :
- English
- ISSN :
- 1938-0666
- Volume :
- 18
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Clinical breast cancer
- Publication Type :
- Academic Journal
- Accession number :
- 29198959
- Full Text :
- https://doi.org/10.1016/j.clbc.2017.11.001